David combines the perspective of a practicing clinician with decades of biopharma management experience. From 1990-2000, he was Medical Director of Chiron Diagnostics, playing a pivotal role in the development of assays for HIV, HCV, HBV, and CMV. He then moved to Elan as VP of Corporate Technology, where he led a team that identified and evaluated dozens of in-licensing opportunities. While at Elan, he was also involved in the clinical development and commercialization of Tysabri and Prialt. He recently spent two years as an Entrepreneur-in-Residence and one year as an operating partner at the venture firm TPG, where he was actively involved in due diligence and in incubating new companies. David has been the acting Chief Medical Officer of several startup biotech companies including Rigel, XDX, CardioDx, Replidyne, Tethys Biosciences, and Neuromolecular Pharmaceuticals. David received a BS in Biology from Yale and an MD from New York University and completed his medical training in internal medicine, rheumatology, and infectious disease at UCSF. He has lectured broadly and published dozens of peer-reviewed articles.